EGFR and neoplasm: Taking into account that EGFR ctDNA shedding status has been previously found to be associated with a baseline tumour target lesion size in AURA3 patients13, our results indicate that AURA3 patients, who are not positive for both the activating and resistance EGFR mutations, may have smaller tumours.